Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mix and Match COVID-19 Vaccines (MOSAIC)
NCT04894435Phase 2Active, not recruiting
- Sponsor
- Canadian Immunization Research Network
- Start
- May 2021
- Primary completion
- Nov 2024
- Modality
- Viral Vector Vaccines, Lipid-based Nanoparticles, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of elasomeran, tozinameran, ChAdOx1 nCoV-19 and Covifenz in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Canadian Immunization Research Network. Primary endpoints: Antibody response to SARS-CoV-2 S protein after 2 doses at Day 140, Antibody response to SARS-CoV-2 S protein after 3 doses at Day 28 and 1 more. Started May 2021; status: active, not recruiting.
02
Drugs
elasomerantozinameranChAdOx1 nCoV-19Covifenz
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04894435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04894435.